Developer docs
API playgroundTry for free, no card

Search company profiles

Pyxis Oncology

Full company profile

uuid0000daq

Namestring
Pyxis Oncology
Legal namestring
Pyxis Oncology, Inc.
Company typeenum
Public
Founded yearint
2019
Descriptiontext

Pyxis Oncology is a Boston-based, NASDAQ-listed (PYXS) clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) and monoclonal antibody immunotherapies for difficult-to-treat cancers, with particular focus on recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Its lead asset, micvotabart pelidotin (MICVO, formerly PYX-201), is a first-in-class non-cellular targeting ADC directed at the extradomain-B splice variant of fibronectin (EDB+FN) in the tumor microenvironment, employing a three-pronged mechanism — direct tumor killing, bystander killing, and immunogenic cell death — via the Aur0101 auristatin payload. The company's technology stack is built on two platforms: the FACT (Flexible Antibody Conjugation Technology) ADC platform, originally developed by Pfizer and providing site-specific conjugation chemistry, linkers, and optimized payloads; and the APXiMAB antibody discovery platform, acquired via the 2024 Apexigen acquisition, which uses proprietary rabbit fusion cell lines and MLG humanization to generate high-affinity antibodies against difficult-to-drug targets. The broader pipeline includes Sotigalimab (a CD40 agonist acquired from Apexigen), PYX-106 (anti-Siglec-15), and PYX-102 (anti-KLRG1).

Pyxis Oncology has no commercial product and generates no product revenue. Its revenue model is currently limited to licensing and royalty streams — including an inherited royalty on a marketed product generated by the APXiMAB platform and a one-time $11M sale of royalty rights to a separate drug in December 2025. The company funds operations primarily through equity financing (a ~$50M post-IPO private placement closed February 2024) and is burning cash at an accelerating rate, with Q1 2026 R&D expenses of $20.0M and net loss of $23.3M versus $17.0M and $21.2M respectively in Q1 2025. With $42.5M in cash as of March 31, 2026, the stated runway extends only into Q4 2026, making capital availability the company's most acute near-term constraint. Customers are not yet end-patients or payers; investigational MICVO is accessed exclusively through clinical trial enrollment at U.S. sites, and the company's most commercially significant partner is Merck, supplying KEYTRUDA (pembrolizumab) for the MICVO combination trial.

Short descriptiontext

Pyxis Oncology is a Boston-based clinical-stage biopharmaceutical company developing antibody-drug conjugates and monoclonal antibody immunotherapies for difficult-to-treat cancers, with lead asset MICVO in Phase 1 development for recurrent/metastatic head and neck squamous cell carcinoma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody-drug conjugates, immuno-oncology therapeutics, cancer antibody discovery, oncology clinical development, tumor microenvironment targeting
Industry1 code
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cancer Therapeutics / Antibody-Drug Conjugates
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Royalty Rights Sale
TypeLicensing Royalties
Description

Sold royalty rights to a separate drug for $11 million in December 2025, extending cash runway through Q4 2026. Royalties from the APXiMAB platform's marketed product also represent an existing royalty stream inherited from Apexigen acquisition.

in.investing.com
2Investment / Equity Financing
TypeSubscription Recurring
Description

Clinical-stage biotech with no product revenue. Generated quarterly revenue of $11.04 million (reported as a 'beat' in one period, though this likely reflects collaboration/royalty accounting). Primary funding source is private placement equity financing (e.g., $50M private placement closed February 2024 at $4.78/share).

defenseworld.net
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1MICVO (micvotabart pelidotin)
Description

Lead investigational antibody-drug conjugate (ADC) targeting extradomain-B splice variant of fibronectin (EDB+FN), formerly known as PYX-201.

pyxisoncology.com
+2 more records
Core offering1 text field

Pyxis Oncology is a clinical-stage biopharmaceutical company that develops investigational antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immuno-oncology therapeutics for difficult-to-treat cancers. Its lead asset, micvotabart pelidotin (MICVO, formerly PYX-201), is a first-in-class ADC targeting extradomain-B splice variant of fibronectin (EDB+FN) in the tumor microenvironment, currently in Phase 1/2 trials as monotherapy and in combination with Merck's KEYTRUDA for recurrent/metastatic head and neck squamous cell carcinoma. The company leverages two proprietary platforms — the FACT ADC platform (originating from Pfizer) and the APXiMAB antibody discovery platform (acquired via Apexigen) — to support next-generation ADC and immuno-oncology candidates including PYX-106 (anti-Siglec-15) and Sotigalimab (CD40 agonist).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 46% confirmed objective response rate as monotherapy and 71% in combination with pembrolizumab in R/M HNSCC Phase 1 trial
+3 more records
Product overview1 text field

Pyxis Oncology is a clinical-stage biopharmaceutical company offering a platform-plus-modules architecture centered on a differentiated portfolio of antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immuno-oncology assets. The FACT Platform (Flexible Antibody Conjugation Technology, originated by Pfizer) provides site-specific conjugation chemistry, linkers, and payloads for next-generation ADCs, while the APXiMAB Platform provides antibody discovery via proprietary rabbit fusion cell lines and MLG humanization. Built on these platforms, the lead clinical asset is the ADC micvotabart pelidotin (MICVO, formerly PYX-201) targeting extradomain-B fibronectin in solid tumors, supplemented by the immuno-oncology candidates PYX-106 (anti-Siglec-15 mAb), PYX-102 (anti-KLRG1 mAb), and the CD40 agonist Sotigalimab (formerly APX005M) acquired through the Apexigen acquisition. Together, these products enable Pyxis Oncology to develop both monotherapies and combination regimens (e.g., MICVO + KEYTRUDA/pembrolizumab) targeting difficult-to-treat cancers.

Product and service4 records
1Micvotabart Pelidotin (MICVO, formerly PYX-201)
CategoryInvestigational ADC / Lead therapeutic candidate
Description

First-in-class investigational antibody-drug conjugate (ADC) targeting extradomain-B splice variant of fibronectin (EDB+FN), an extracellular matrix protein selectively overexpressed in tumor microenvironment. In Phase 1 trials as monotherapy and in combination with KEYTRUDA (pembrolizumab) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) and other solid tumors. U.S. FDA granted Fast Track Designation for R/M HNSCC.

2PYX-106
CategoryInvestigational monoclonal antibody (immuno-oncology candidate)
Description

Highly differentiated anti-Siglec-15 monoclonal antibody designed to reverse Siglec-15 mediated immune suppression and enhance cytotoxic activity in human lymphocytes; was in Phase 1 development for advanced solid tumors with data anticipated by year-end.

3Sotigalimab (formerly APX005M / PYX-107)
CategoryInvestigational monoclonal antibody (CD40 agonist immuno-oncology candidate)
Description

CD40 agonistic monoclonal antibody acquired via the Apexigen acquisition, described as a potential best-in-class CD40 agonist. Investigated across multiple oncology indications including metastatic melanoma, pancreatic adenocarcinoma, esophageal/GEJ cancers, and sarcoma, both as monotherapy and in combination with chemotherapy, radiotherapy, and checkpoint inhibitors.

4PYX-102
CategoryPreclinical monoclonal antibody (immuno-oncology candidate)
Description

Anti-KLRG1 antibody that enhances cytotoxic activity of CD8 T cells from PBMC and human tumor samples by blocking the interaction between KLRG1 and cadherins.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierMajor M&A — Platform TransformingTypeStrategic or Co-development PartnerAnnounced on2023-05-01
Description

Pyxis Oncology completed acquisition of Apexigen in an all-stock deal valued at approximately $10.7 million (with prior announcement value of ~$16 million). Acquisition expanded Pyxis Oncology's antibody and ADC platform, added a Phase 2 candidate and royalty stream, and brought in the APXiMAB antibody discovery platform and Sotigalimab (CD40 agonist).

Strategic tierFlagship Clinical Combination PartnerTypeStrategic or Co-development Partner
Description

Clinical combination partnership evaluating MICVO with Merck's KEYTRUDA (pembrolizumab) in Phase 1/2 study (NCT06795412) for recurrent/metastatic head and neck squamous cell carcinoma. KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Updated combination data expected in 2H 2026.

Strategic tierCore Technology Platform OriginatorTypeStrategic or Co-development Partner
Description

FACT (Flexible Antibody Conjugation Technology) ADC platform was developed by Pfizer and provides Pyxis Oncology with site-specific conjugation chemistries, improved linker technology, and optimized payloads for next-generation ADC development. Pfizer is also listed as a financial investor on the company website.

Strategic tierAdvisory RelationshipTypeOthers
Description

Paul A. Bunn, Jr, M.D., FASCO, FACP, FAAAS from University of Colorado Cancer Center serves on Pyxis Oncology's Clinical and Translational Medicine Advisory Board.

Strategic tierAdvisory RelationshipTypeOthers
Description

Giulio Draetta, M.D., Ph.D. from UT MD Anderson Cancer Center serves on Pyxis Oncology's Clinical and Translational Medicine Advisory Board.

Strategic tierAdvisory RelationshipTypeOthers
Description

Patricia LoRusso, D.O., Ph.D. (hc) from Yale University, Yale Cancer Center serves on Pyxis Oncology's Clinical and Translational Medicine Advisory Board.

Strategic tierAdvisory RelationshipTypeOthers
Description

Jason J. Luke, M.D., FACP from UPMC Hillman Cancer Center, University of Pittsburgh serves on Pyxis Oncology's Clinical and Translational Medicine Advisory Board.

Strategic tierAdvisory RelationshipTypeOthers
Description

Anthony W. Tolcher, M.D., FRCPC, FACP from NEXT Oncology serves on Pyxis Oncology's Clinical and Translational Medicine Advisory Board.

Strategic tierAdvisory RelationshipTypeOthers
Description

Robert Baffi, Ph.D., MBA, President of Global Manufacturing & Technical Operations at BioMarin, serves on Pyxis Oncology's Technical Advisory Board.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Mersana Therapeutics is a clinical-stage ADC developer with proprietary platforms (Dolasynthen, Immunosynthen) advancing first-in-class and best-in-class ADCs in oncology, comparable to Pyxis Oncology in stage, business model, and ADC-centric clinical focus.

TypeDirect peer
Description

ADC Therapeutics is a commercial-stage ADC company developing pyrrolobenzodiazepine-based ADCs (Zynlonta) for hematologic and solid tumors, comparable to Pyxis Oncology as a fellow ADC-focused oncology developer with platform-based pipeline strategy.

TypeDirect peer
Description

ImmunoGen developed the ADC platform behind Elahere (mirvetuximab) and was acquired by AbbVie in 2024, making it a direct precedent for ADC-platform M&A and a comparable ADC developer in ovarian and other solid tumors.

TypeEmerging player
Description

ProfoundBio is a clinical-stage ADC developer with multiple candidates in oncology including FRα and CDH17-targeted ADCs, comparable to Pyxis Oncology in clinical stage, ADC focus, and targeted-oncology development approach.

TypeEmerging player
Description

Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates (ISACs) that combine ADC-like targeting with innate immune activation, comparable to Pyxis in stage, oncology focus, and antibody-conjugate therapeutic modality.

TypeEmerging player
Description

Tubulis is a clinical-stage ADC developer focused on next-generation linkers, payloads, and conjugation chemistries to improve therapeutic index, directly comparable to Pyxis's FACT platform focus on linker and conjugation technology advancement.

TypeBroad incumbent
Description

Daiichi Sankyo co-developed Enhertu and Datroway with AstraZeneca, making it the leading commercial ADC player and a broad incumbent whose pipeline defines the competitive benchmark for clinical-stage ADC developers like Pyxis Oncology.

TypeBroad incumbent
Description

AstraZeneca is a global oncology leader with the Enhertu/Datroway ADC franchise and broad immuno-oncology portfolio, serving as a broad incumbent competitor whose checkpoint-inhibitor combination strategy parallels Pyxis Oncology's MICVO + KEYTRUDA development path.

TypeBroad incumbent
Description

Pfizer originated the FACT ADC platform licensed to Pyxis Oncology and maintains a broad oncology and ADC pipeline (including Padcev via Seagen acquisition), making it both a technology licensor and broad incumbent competitor.

10Mythic Therapeutics
TypeEmerging player
Description

Mythic Therapeutics is a clinical-stage ADC developer focused on solid tumors, comparable to Pyxis Oncology as a fellow emerging ADC biotech targeting oncology indications with antibody-conjugate technology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors28 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pyxis Oncology

Cancer Therapeutics / Antibody-Drug Conjugatespyxisoncology.com

Pyxis Oncology is a Boston-based clinical-stage biopharmaceutical company developing antibody-drug conjugates and monoclonal antibody immunotherapies for difficult-to-treat cancers, with lead asset MICVO in Phase 1 development for recurrent/metastatic head and neck squamous cell carcinoma.

What Pyxis Oncology does

Pyxis Oncology is a Boston-based, NASDAQ-listed (PYXS) clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) and monoclonal antibody immunotherapies for difficult-to-treat cancers, with particular focus on recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Its lead asset, micvotabart pelidotin (MICVO, formerly PYX-201), is a first-in-class non-cellular targeting ADC directed at the extradomain-B splice variant of fibronectin (EDB+FN) in the tumor microenvironment, employing a three-pronged mechanism — direct tumor killing, bystander killing, and immunogenic cell death — via the Aur0101 auristatin payload. The company's technology stack is built on two platforms: the FACT (Flexible Antibody Conjugation Technology) ADC platform, originally developed by Pfizer and providing site-specific conjugation chemistry, linkers, and optimized payloads; and the APXiMAB antibody discovery platform, acquired via the 2024 Apexigen acquisition, which uses proprietary rabbit fusion cell lines and MLG humanization to generate high-affinity antibodies against difficult-to-drug targets. The broader pipeline includes Sotigalimab (a CD40 agonist acquired from Apexigen), PYX-106 (anti-Siglec-15), and PYX-102 (anti-KLRG1).

Pyxis Oncology has no commercial product and generates no product revenue. Its revenue model is currently limited to licensing and royalty streams — including an inherited royalty on a marketed product generated by the APXiMAB platform and a one-time $11M sale of royalty rights to a separate drug in December 2025. The company funds operations primarily through equity financing (a ~$50M post-IPO private placement closed February 2024) and is burning cash at an accelerating rate, with Q1 2026 R&D expenses of $20.0M and net loss of $23.3M versus $17.0M and $21.2M respectively in Q1 2025. With $42.5M in cash as of March 31, 2026, the stated runway extends only into Q4 2026, making capital availability the company's most acute near-term constraint. Customers are not yet end-patients or payers; investigational MICVO is accessed exclusively through clinical trial enrollment at U.S. sites, and the company's most commercially significant partner is Merck, supplying KEYTRUDA (pembrolizumab) for the MICVO combination trial.

Pyxis Oncology firmographics

Firmographics
Name
Pyxis Oncology
Legal name
Pyxis Oncology, Inc.
Website
https://pyxisoncology.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Pyxis Oncology is a Boston-based clinical-stage biopharmaceutical company developing antibody-drug conjugates and monoclonal antibody immunotherapies for difficult-to-treat cancers, with lead asset MICVO in Phase 1 development for recurrent/metastatic head and neck squamous cell carcinoma.
Ownership category
akta.pro rank

Pyxis Oncology industry classification

Industry
Product category
Cancer Therapeutics / Antibody-Drug Conjugates
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Antibody-drug conjugates
  • Immuno-oncology therapeutics
  • Cancer antibody discovery
  • Oncology clinical development
  • Tumor microenvironment targeting

Where Pyxis Oncology is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Pyxis Oncology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Royalty Rights Sale: Sold royalty rights to a separate drug for $11 million in December 2025, extending cash runway through Q4 2026. Royalties from the APXiMAB platform's marketed product also represent an existing royalty stream inherited from Apexigen acquisition.
  2. Investment / Equity Financing: Clinical-stage biotech with no product revenue. Generated quarterly revenue of $11.04 million (reported as a 'beat' in one period, though this likely reflects collaboration/royalty accounting). Primary funding source is private placement equity financing (e.g., $50M private placement closed February 2024 at $4.78/share).

Go-to-market motion3 records

Distribution channels1 record

Marketing channels6 records

Pyxis Oncology product offering

Product offering

Core offering

Pyxis Oncology is a clinical-stage biopharmaceutical company that develops investigational antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immuno-oncology therapeutics for difficult-to-treat cancers. Its lead asset, micvotabart pelidotin (MICVO, formerly PYX-201), is a first-in-class ADC targeting extradomain-B splice variant of fibronectin (EDB+FN) in the tumor microenvironment, currently in Phase 1/2 trials as monotherapy and in combination with Merck's KEYTRUDA for recurrent/metastatic head and neck squamous cell carcinoma. The company leverages two proprietary platforms — the FACT ADC platform (originating from Pfizer) and the APXiMAB antibody discovery platform (acquired via Apexigen) — to support next-generation ADC and immuno-oncology candidates including PYX-106 (anti-Siglec-15) and Sotigalimab (CD40 agonist).

Product overview

Pyxis Oncology is a clinical-stage biopharmaceutical company offering a platform-plus-modules architecture centered on a differentiated portfolio of antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immuno-oncology assets. The FACT Platform (Flexible Antibody Conjugation Technology, originated by Pfizer) provides site-specific conjugation chemistry, linkers, and payloads for next-generation ADCs, while the APXiMAB Platform provides antibody discovery via proprietary rabbit fusion cell lines and MLG humanization. Built on these platforms, the lead clinical asset is the ADC micvotabart pelidotin (MICVO, formerly PYX-201) targeting extradomain-B fibronectin in solid tumors, supplemented by the immuno-oncology candidates PYX-106 (anti-Siglec-15 mAb), PYX-102 (anti-KLRG1 mAb), and the CD40 agonist Sotigalimab (formerly APX005M) acquired through the Apexigen acquisition. Together, these products enable Pyxis Oncology to develop both monotherapies and combination regimens (e.g., MICVO + KEYTRUDA/pembrolizumab) targeting difficult-to-treat cancers.

Differentiator

Problem solved

Functional benefit

Brands

  • MICVO (micvotabart pelidotin): Lead investigational antibody-drug conjugate (ADC) targeting extradomain-B splice variant of fibronectin (EDB+FN), formerly known as PYX-201.
  • FACT (Flexible Antibody Conjugation Technology)
  • APXiMAB

Products and services

  • Micvotabart Pelidotin (MICVO, formerly PYX-201) First-in-class investigational antibody-drug conjugate (ADC) targeting extradomain-B splice variant of fibronectin (EDB+FN), an extracellular matrix protein selectively overexpressed in tumor microenvironment. In Phase 1 trials as monotherapy and in combination with KEYTRUDA (pembrolizumab) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) and other solid tumors. U.S. FDA granted Fast Track Designation for R/M HNSCC.
  • PYX-106 Highly differentiated anti-Siglec-15 monoclonal antibody designed to reverse Siglec-15 mediated immune suppression and enhance cytotoxic activity in human lymphocytes; was in Phase 1 development for advanced solid tumors with data anticipated by year-end.
  • Sotigalimab (formerly APX005M / PYX-107) CD40 agonistic monoclonal antibody acquired via the Apexigen acquisition, described as a potential best-in-class CD40 agonist. Investigated across multiple oncology indications including metastatic melanoma, pancreatic adenocarcinoma, esophageal/GEJ cancers, and sarcoma, both as monotherapy and in combination with chemotherapy, radiotherapy, and checkpoint inhibitors.
  • PYX-102 Anti-KLRG1 antibody that enhances cytotoxic activity of CD8 T cells from PBMC and human tumor samples by blocking the interaction between KLRG1 and cadherins.

Quantifiable outcome

  • 46% confirmed objective response rate as monotherapy and 71% in combination with pembrolizumab in R/M HNSCC Phase 1 trial
  • +3 more outcomes

Companies that use Pyxis Oncology

Customer profile

Named customers1 record

Ideal customer profiles2 records

Pyxis Oncology technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Pyxis Oncology partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered major m&a — platform transforming, flagship clinical combination partner, core technology platform originator and advisory relationship.

  • Apexigenmajor m&a — platform transformingStrategic or Co-development Partner · 1 May 2023Pyxis Oncology completed acquisition of Apexigen in an all-stock deal valued at approximately $10.7 million (with prior announcement value of ~$16 million). Acquisition expanded Pyxis Oncology's antibody and ADC platform, added a Phase 2 candidate and royalty stream, and brought in the APXiMAB antibody discovery platform and Sotigalimab (CD40 agonist).
  • Merck (KEYTRUDA / pembrolizumab)flagship clinical combination partnerStrategic or Co-development PartnerClinical combination partnership evaluating MICVO with Merck's KEYTRUDA (pembrolizumab) in Phase 1/2 study (NCT06795412) for recurrent/metastatic head and neck squamous cell carcinoma. KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Updated combination data expected in 2H 2026.
  • Pfizercore technology platform originatorStrategic or Co-development PartnerFACT (Flexible Antibody Conjugation Technology) ADC platform was developed by Pfizer and provides Pyxis Oncology with site-specific conjugation chemistries, improved linker technology, and optimized payloads for next-generation ADC development. Pfizer is also listed as a financial investor on the company website.
  • University of Colorado Cancer Centeradvisory relationshipOthersPaul A. Bunn, Jr, M.D., FASCO, FACP, FAAAS from University of Colorado Cancer Center serves on Pyxis Oncology's Clinical and Translational Medicine Advisory Board.
  • UT MD Anderson Cancer Centeradvisory relationshipOthersGiulio Draetta, M.D., Ph.D. from UT MD Anderson Cancer Center serves on Pyxis Oncology's Clinical and Translational Medicine Advisory Board.
  • Yale University, Yale Cancer Centeradvisory relationshipOthersPatricia LoRusso, D.O., Ph.D. (hc) from Yale University, Yale Cancer Center serves on Pyxis Oncology's Clinical and Translational Medicine Advisory Board.
  • UPMC Hillman Cancer Center, University of Pittsburghadvisory relationshipOthersJason J. Luke, M.D., FACP from UPMC Hillman Cancer Center, University of Pittsburgh serves on Pyxis Oncology's Clinical and Translational Medicine Advisory Board.
  • NEXT Oncologyadvisory relationshipOthersAnthony W. Tolcher, M.D., FRCPC, FACP from NEXT Oncology serves on Pyxis Oncology's Clinical and Translational Medicine Advisory Board.
  • BioMarin Pharmaceuticaladvisory relationshipOthersRobert Baffi, Ph.D., MBA, President of Global Manufacturing & Technical Operations at BioMarin, serves on Pyxis Oncology's Technical Advisory Board.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Pyxis Oncology competitors and assessment

Company assessment

Direct peers

  • Mersana Therapeutics: Mersana Therapeutics is a clinical-stage ADC developer with proprietary platforms (Dolasynthen, Immunosynthen) advancing first-in-class and best-in-class ADCs in oncology, comparable to Pyxis Oncology in stage, business model, and ADC-centric clinical focus.
  • ADC Therapeutics: ADC Therapeutics is a commercial-stage ADC company developing pyrrolobenzodiazepine-based ADCs (Zynlonta) for hematologic and solid tumors, comparable to Pyxis Oncology as a fellow ADC-focused oncology developer with platform-based pipeline strategy.
  • ImmunoGen (AbbVie): ImmunoGen developed the ADC platform behind Elahere (mirvetuximab) and was acquired by AbbVie in 2024, making it a direct precedent for ADC-platform M&A and a comparable ADC developer in ovarian and other solid tumors.

Emerging players

  • ProfoundBio: ProfoundBio is a clinical-stage ADC developer with multiple candidates in oncology including FRα and CDH17-targeted ADCs, comparable to Pyxis Oncology in clinical stage, ADC focus, and targeted-oncology development approach.
  • Bolt Biotherapeutics: Bolt Biotherapeutics is a clinical-stage immuno-oncology company developing immune-stimulating antibody conjugates (ISACs) that combine ADC-like targeting with innate immune activation, comparable to Pyxis in stage, oncology focus, and antibody-conjugate therapeutic modality.
  • Tubulis: Tubulis is a clinical-stage ADC developer focused on next-generation linkers, payloads, and conjugation chemistries to improve therapeutic index, directly comparable to Pyxis's FACT platform focus on linker and conjugation technology advancement.
  • Mythic Therapeutics: Mythic Therapeutics is a clinical-stage ADC developer focused on solid tumors, comparable to Pyxis Oncology as a fellow emerging ADC biotech targeting oncology indications with antibody-conjugate technology.

Broad incumbents

  • Daiichi Sankyo: Daiichi Sankyo co-developed Enhertu and Datroway with AstraZeneca, making it the leading commercial ADC player and a broad incumbent whose pipeline defines the competitive benchmark for clinical-stage ADC developers like Pyxis Oncology.
  • AstraZeneca: AstraZeneca is a global oncology leader with the Enhertu/Datroway ADC franchise and broad immuno-oncology portfolio, serving as a broad incumbent competitor whose checkpoint-inhibitor combination strategy parallels Pyxis Oncology's MICVO + KEYTRUDA development path.
  • Pfizer: Pfizer originated the FACT ADC platform licensed to Pyxis Oncology and maintains a broad oncology and ADC pipeline (including Padcev via Seagen acquisition), making it both a technology licensor and broad incumbent competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Pyxis Oncology social profiles

Digital presence

Pyxis Oncology compliance and trust

Trust signal

Compliance1 record

Pyxis Oncology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pyxis Oncology leadership team

Management profile

Number of profiles

Profiles16 records

Pyxis Oncology subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Pyxis Oncology funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors28 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pyxis Oncology M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pyxis Oncology

What does Pyxis Oncology do?

Pyxis Oncology is a clinical-stage biopharmaceutical company that develops investigational antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immuno-oncology therapeutics for difficult-to-treat cancers. Its lead asset, micvotabart pelidotin (MICVO, formerly PYX-201), is a first-in-class ADC targeting extradomain-B splice variant of fibronectin (EDB+FN) in the tumor microenvironment, currently in Phase 1/2 trials as monotherapy and in combination with Merck's KEYTRUDA for recurrent/metastatic head and neck squamous cell carcinoma. The company leverages two proprietary platforms — the FACT ADC platform (originating from Pfizer) and the APXiMAB antibody discovery platform (acquired via Apexigen) — to support next-generation ADC and immuno-oncology candidates including PYX-106 (anti-Siglec-15) and Sotigalimab (CD40 agonist).

Is Pyxis Oncology a public or private company?

Pyxis Oncology is a public company. It is classified as public and is currently operating.

When was Pyxis Oncology founded?

Pyxis Oncology was founded in 2019. It employs 51 to 100 people.

Where is Pyxis Oncology based?

Pyxis Oncology is headquartered in Boston, United States, in the North America region.

How does Pyxis Oncology make money?

Two revenue lines are on record. Royalty Rights Sale is the primary driver. The others are investment / Equity Financing.

Who are Pyxis Oncology's main competitors?

Direct peers on record are Mersana Therapeutics, ADC Therapeutics and ImmunoGen (AbbVie). Emerging players are ProfoundBio, Bolt Biotherapeutics, Tubulis and Mythic Therapeutics. Broad incumbents are Daiichi Sankyo, AstraZeneca and Pfizer.

Does Pyxis Oncology have an API?

No public API is recorded for Pyxis Oncology.

What industry is Pyxis Oncology in?

Pyxis Oncology's product category is Cancer Therapeutics / Antibody-Drug Conjugates. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingPyxis Oncology reports 39% confirmed response rate for MICVO in Phase 1 head and neck cancer trialPyxis Oncology reported Phase 1 results for MICVO in previously treated recurrent or metastatic head and neck cancer, showing a 39% confirmed response rate. The findings support plans to initiate the global Phase 3 Headliner trial in mid-2027, with results to be presented at the EORTC-NCI-AACR Symposium in Barcelona on November 19, 2026.TradingViewPyxis Oncology (PYXS) Reports 39% Confirmed MICVO Response RatePyxis Oncology reported a 39% confirmed response rate for MICVO in 33 evaluable patients from an updated Phase 1 study. The data also showed a 9.2-month median response duration and 6.7-month median progression-free survival. The company plans to initiate a global Phase 3 trial in mid-2027.Simply Wall StWe're Keeping An Eye On Pyxis Oncology's (NASDAQ:PYXS) Cash Burn RatePyxis Oncology's cash burn of $71m gives it a 9-month cash runway as of September 2026, with $56m in cash and no debt. Its operating revenue grew 291% over the past year, but the high burn relative to its $169m market cap raises concerns about raising additional capital.Investing.comPyxis Pharmaceuticals at Guggenheim conference: pushing MICVO forwardPyxis Pharmaceuticals presented MICVO data at the Guggenheim conference, citing a 36% overall response rate and 79% 12-month survival probability in heavily pre-treated head and neck cancer patients. The company plans a Phase III Headliner trial with first patient dosing in mid-2027, targeting over 20,000 U.S. second-line patients.Defense WorldPyxis Oncology (NASDAQ:PYXS) Stock Price Target Cut by WedbushWedbush cut its price target on Pyxis Oncology from $8.00 to $7.00, keeping an outperform rating. The stock opened at $1.66, with a consensus rating of Moderate Buy and an average target of $8.71. Analysts forecast a fiscal-year EPS of -$1.21.TradingViewRBC Capital maintains Pyxis Oncology at Outperform, raises price target to $7 from $6RBC Capital maintained Pyxis Oncology at Outperform and raised its price target to $7 from $6, a 16.7% increase. The target implies an upside of 334.8% from the Nov 5 close of $1.61.TradingViewWedbush maintains Pyxis Oncology at Outperform, lowers price target to $7 from $8Wedbush maintained Pyxis Oncology at Outperform and lowered its price target to $7 from $8, a 12.5% decrease. The target implies an upside of 334.8% from the Nov 5 close of $1.61.MarketBeatPyxis Oncology, Inc. (NASDAQ:PYXS) Stock Has Consensus Price Target of $8.75 According to BrokeragesPyxis Oncology shares have an average analyst rating of Moderate Buy with a 12-month price target of $8.75. The stock opened at $1.98, and T3 Companies LLC acquired a new stake of 26,100 shares in Q3. Analysts expect a loss of $1.21 per share for the current year.Business & FinancialPyxis Oncology To Participate In Upcoming Investor ConferencesPyxis Oncology will present at Guggenheim and Stifel investor conferences in November 2026. Its lead ADC MICVO targets fibronectin in solid tumors and is in Phase 1/2 trials for head and neck cancer. The company aims to advance MICVO for recurrent and metastatic disease.